High homocysteine has not been shown to cause miscarriages in clinical trials, although observational studies link elevated levels to recurrent pregnancy loss, and professional guidelines do not recommend routine testing before conception. At Longevity Benchmark, we review clinical trial literature and professional guidelines to help readers separate genuine risk markers from unvalidated tests. During a normal pregnancy, homocysteine concentrations fall rather than rise, driven by plasma expansion, increased renal clearance, and fetal uptake.
The Verdict
Homocysteine and Pregnancy Loss: What the Evidence Shows
Homocysteine concentrations drop during an uncomplicated pregnancy, yet elevated levels show an association with recurrent pregnancy loss and preeclampsia in observational research, even as professional guidelines recommend against routine screening. A 2026 meta-analysis of 13 case-control studies published by Du and colleagues in Frontiers in Endocrinology evaluated 1,473 women with unexplained recurrent pregnancy loss and 1,605 controls. The analysis identified an odds ratio of 3.46 (95% CI 2.33 to 5.14) for elevated homocysteine in women experiencing recurrent loss.
The authors of the meta-analysis emphasized that their findings demonstrate correlation rather than causation. In their own limiting conclusion, the investigators noted that while underlying mechanisms likely involve vascular dysfunction, placental impairment, and immune dysregulation, the observational nature of the evidence precludes causal inference. Because all included investigations were case-control studies, the dataset remains inherently susceptible to selection bias and cannot establish that elevated homocysteine causes pregnancy loss.
In addition, no clinical intervention trials have demonstrated that reducing homocysteine levels lowers the risk of subsequent miscarriages. Medical guidelines avoid recommending diagnostic tests when the resulting data does not alter management or improve clinical outcomes. Without randomized trials proving that lowering homocysteine protects a pregnancy, the observed statistical association does not justify screening.
Normal Homocysteine Levels During Pregnancy
Maternal homocysteine levels decline during healthy pregnancies, following a distinct pattern across the three trimesters. According to a 2026 review by An and colleagues in Frontiers in Endocrinology, plasma homocysteine concentrations in pregnant individuals are typically lower than in non-pregnant individuals and follow a U-shaped curve: decreasing in the first trimester, reaching a nadir in the second, and gradually rising in the third.
In normal pregnancies, maternal homocysteine concentrations range from 5.43 to 9.42 micromol/L, with a gradual decline observed across the second and third trimesters. This physiologic reduction occurs due to hemodilution from increased plasma volume, enhanced glomerular filtration in the kidneys, and fetal uptake of homocysteine. Folic acid and vitamin B12 supplementation supports this decline by promoting the conversion of homocysteine to methionine via the remethylation pathway.
Laboratories generally do not use uniform reference ranges for pregnant patients. As An and colleagues noted, there is no uniform standard for the reference interval of homocysteine in pregnancy. Because commercial laboratory reference ranges are derived from non-pregnant populations, evaluating a pregnancy blood draw against standard adult reference intervals can produce misleading interpretations.
Preeclampsia and Other Pregnancy Complications
Elevated maternal homocysteine is associated with several gestational complications in observational studies, although the underlying data exhibits high statistical heterogeneity. A 2026 meta-analysis of 13 observational studies conducted by Abu-Zaid and colleagues in the Journal of Clinical Medicine evaluated pooled risks across multiple pregnancy outcomes. The review reported that elevated maternal homocysteine was associated with preeclampsia at an odds ratio of 2.49 (95% CI 1.41 to 4.40 across 9 studies) and preterm birth at an odds ratio of 4.01 (95% CI 1.84 to 8.72 across 6 studies).
The statistical heterogeneity for these primary findings was substantial, with an I-squared value of 96.03% for preeclampsia and 91.08% for preterm birth, indicating marked divergence among the included studies. The same meta-analysis identified pooled associations for fetal loss with an odds ratio of 1.76 (95% CI 1.22 to 2.52, I-squared 41.47% across 6 studies), small for gestational age infants with an odds ratio of 1.69 (95% CI 1.35 to 2.11, I-squared 0.00% across 3 studies), and low birth weight with an odds ratio of 2.46 (95% CI 1.37 to 4.43, I-squared 77.71% across 3 studies).
The authors of the review noted that maternal homocysteine concentrations are strongly influenced by folic acid supplementation, serum folate levels, and vitamin B12 status, which were not consistently adjusted for across the evaluated studies. Furthermore, both the Abu-Zaid and Du meta-analyses were published in 2026 and have not yet been widely replicated in subsequent obstetric research.
Clinical Guidelines on MTHFR and Homocysteine Testing
Professional medical organizations consistently advise against ordering routine MTHFR genetic testing or fasting homocysteine panels during recurrent pregnancy loss evaluations. Practice guidelines from the American College of Medical Genetics and Genomics, as cited by The ObG Project, state that MTHFR polymorphism genotyping should not be ordered as part of the clinical evaluation for thrombophilia or recurrent pregnancy loss or for at-risk family members.
The American College of Obstetricians and Gynecologists, as quoted in Aetna Clinical Policy Bulletin 0348, states that screening with either MTHFR mutation analyses or fasting homocysteine levels is not recommended. The bulletin notes that testing for MTHFR mutations is not recommended for recurrent pregnancy loss because only antiphospholipid syndrome has shown consistent associations with loss. Furthermore, ACOG documentation quoted in the policy emphasizes that there is a lack of association between heterozygosity or homozygosity for the common 677C>T polymorphism and negative pregnancy outcomes.
Major insurers reflect these clinical society positions in their coverage determinations. In Clinical Policy Bulletin 0348, Aetna categorizes MTHFR testing as experimental or investigational for recurrent pregnancy loss evaluations. Additionally, Aetna Clinical Policy Bulletin 0763 lists homocysteine testing as experimental, investigational, or unproven for both the assessment of recurrent pregnancy loss and the assessment of preeclampsia. An MTHFR result changes nothing a clinician would do next, and it can frighten someone over a finding that carries no management implication.
Folic Acid Guidelines and Preconception Support
Standard periconceptional folic acid supplementation remains the proven nutritional intervention for early embryonic development, independent of maternal homocysteine testing. The Centers for Disease Control and Prevention recommends that all women capable of becoming pregnant should get 400 micrograms (mcg) of folic acid daily. This intake should begin at least one month before conception and continue through pregnancy.
The CDC establishes this daily 400 mcg recommendation because adequate folic acid intake helps prevent serious birth defects known as neural tube defects. These neural tube defects develop during the first few weeks of pregnancy, often before an individual realizes they are pregnant. Folic acid supports the remethylation pathway that recycles homocysteine into methionine, but the clinical objective of supplementation is structural neural development rather than achieving a specific homocysteine blood target.
No clinical trial evidence exists demonstrating that high-dose folate supplementation or treatments targeted at lowering homocysteine reduce the incidence of miscarriage or preeclampsia. General information on nutritional cofactors in non-pregnant populations is detailed in our guide to vitamin B12 deficiency, while broader systemic causes of elevated levels are discussed in our overview of homocysteine testing. Individual nutritional requirements during pregnancy should always be guided by a licensed healthcare provider.
Evaluations for Recurrent Pregnancy Loss
Standard medical evaluations for recurrent pregnancy loss focus on conditions with established diagnostic and therapeutic interventions rather than methylation panels. Diagnostic protocols recommended by obstetric specialists prioritize validated causes such as parental chromosomal abnormalities, uterine anatomic defects, endocrine disorders, and autoimmune factors. Specifically, antiphospholipid syndrome represents the primary thrombophilia with documented clinical evidence linking it to pregnancy complications and guided medical treatment.
The central reason professional organizations do not endorse routine homocysteine or MTHFR screening is that a positive test result does not lead to an effective, evidence-based treatment. Genetic variants such as MTHFR C677T are common in the general population, and observational associations from case-control studies have not translated into successful therapeutic trials. When a diagnostic test cannot guide clinical management, ordering it provides no actionable benefit to patient care.
ACOG and the ACMG both advise against these tests in this setting. Any decision about your own workup belongs with your obstetrician.
Frequently Asked Questions
Can high homocysteine cause a miscarriage?
High homocysteine has not been shown to cause miscarriages in clinical trials. A 2026 meta-analysis of 13 case-control studies found that women with unexplained recurrent pregnancy loss had higher odds of elevated homocysteine, with an odds ratio of 3.46. However, the study authors emphasized that their findings demonstrate an association rather than causation, noting that observational case-control studies are prone to selection bias. No interventional studies have proven that lowering homocysteine prevents pregnancy loss, which is why clinical guidelines do not treat it as a direct cause.
Should I get a homocysteine blood test before getting pregnant?
Neither ACOG nor the ACMG recommends routine homocysteine blood testing before attempting to conceive. Guidelines from ACOG, as quoted in Aetna Clinical Policy Bulletin 0348, explicitly state that screening with fasting homocysteine levels is not recommended for recurrent pregnancy loss evaluations. Major payers, including Aetna under Clinical Policy Bulletin 0763, classify homocysteine testing as experimental and investigational for evaluating pregnancy loss and preeclampsia. Because measuring homocysteine does not alter preconception clinical management, routine screening is not endorsed.
How do homocysteine levels change during a normal pregnancy?
Homocysteine concentrations naturally decline during a healthy pregnancy, following a U-shaped trajectory across trimesters. A 2026 review in Frontiers in Endocrinology found that maternal concentrations typically range between 5.43 and 9.42 micromol/L, decreasing in the first trimester, reaching their lowest point in the second trimester, and gradually rising in the third. This reduction is driven by hemodilution from increased plasma volume, higher glomerular filtration rates, and fetal uptake. The review also highlighted that there is currently no uniform reference interval established for homocysteine during pregnancy.
Does having an MTHFR gene mutation affect pregnancy outcomes?
Having an MTHFR gene variant has not been shown to worsen pregnancy outcomes in clinical evaluations. Practice guidelines from the American College of Medical Genetics and Genomics advise against ordering MTHFR polymorphism genotyping for recurrent pregnancy loss. Furthermore, ACOG, as quoted in Aetna Clinical Policy Bulletin 0348, notes that testing is not recommended because common variants, such as 677C>T, lack association with negative pregnancy outcomes. An MTHFR result does not change clinical management and is considered experimental by major medical insurers.
What is the recommended folic acid dose before and during pregnancy?
The Centers for Disease Control and Prevention recommends that all women capable of becoming pregnant take 400 micrograms of folic acid daily. This supplementation should begin at least one month before conception and continue throughout pregnancy to help prevent neural tube defects. These serious birth defects develop in the earliest weeks of embryonic growth, often before a person knows they are pregnant. There is no clinical trial evidence showing that taking higher doses of folic acid to target homocysteine levels improves pregnancy outcomes.
Is elevated homocysteine linked to preeclampsia?
Observational research shows an association between high maternal homocysteine and preeclampsia, but the underlying studies display substantial statistical disagreement. A 2026 meta-analysis published in the Journal of Clinical Medicine reported an odds ratio of 2.49 for preeclampsia among women with elevated homocysteine, but with an I-squared heterogeneity of 96.03%. The authors cautioned that maternal homocysteine is heavily influenced by maternal folate and vitamin B12 status, which were not consistently controlled across studies. Clinical guidelines do not recommend testing homocysteine to assess preeclampsia risk.